Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.12
HZNP's Cash to Debt is ranked higher than
69% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. HZNP: 1.12 )
HZNP' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 1.12

Equity to Asset 0.25
HZNP's Equity to Asset is ranked lower than
52% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. HZNP: 0.25 )
HZNP' s 10-Year Equity to Asset Range
Min: -0.77   Max: 0.7
Current: 0.25

-0.77
0.7
F-Score: 4
Z-Score: -3.78
M-Score: 0.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -8.22
HZNP's Operating margin (%) is ranked higher than
55% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. HZNP: -8.22 )
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5   Max: -57.9
Current: -8.22

-1841.5
-57.9
Net-margin (%) -200.74
HZNP's Net-margin (%) is ranked lower than
52% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. HZNP: -200.74 )
HZNP' s 10-Year Net-margin (%) Range
Min: -1635.12   Max: -201.31
Current: -200.74

-1635.12
-201.31
ROE (%) -523.78
HZNP's ROE (%) is ranked lower than
56% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. HZNP: -523.78 )
HZNP' s 10-Year ROE (%) Range
Min: -523.78   Max: -57.66
Current: -523.78

-523.78
-57.66
ROA (%) -143.05
HZNP's ROA (%) is ranked lower than
56% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. HZNP: -143.05 )
HZNP' s 10-Year ROA (%) Range
Min: -176.97   Max: -31.86
Current: -143.05

-176.97
-31.86
ROC (Joel Greenblatt) (%) -374.20
HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. HZNP: -374.20 )
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5030.52   Max: -1142.01
Current: -374.2

-5030.52
-1142.01
Revenue Growth (%) -14.60
HZNP's Revenue Growth (%) is ranked higher than
52% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. HZNP: -14.60 )
HZNP' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -14.6
Current: -14.6

EBITDA Growth (%) -74.50
HZNP's EBITDA Growth (%) is ranked lower than
53% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. HZNP: -74.50 )
HZNP' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -74.5
Current: -74.5

EPS Growth (%) -52.00
HZNP's EPS Growth (%) is ranked higher than
52% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. HZNP: -52.00 )
HZNP' s 10-Year EPS Growth (%) Range
Min: 0   Max: -52
Current: -52

» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

HZNP Guru Trades in Q4 2012

Columbia Wanger Sold Out
» More
Q4 2013

HZNP Guru Trades in Q4 2013

Paul Tudor Jones 14,646 sh (New)
Jim Simons 358,000 sh (New)
» More
Q1 2014

HZNP Guru Trades in Q1 2014

Paul Tudor Jones 16,733 sh (+14.25%)
Jim Simons Sold Out
» More
Q2 2014

HZNP Guru Trades in Q2 2014

Joel Greenblatt 57,769 sh (New)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.01%$12.02 - $16.32 $ 11.89-17%57769
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 10.90
HZNP's P/B is ranked higher than
51% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. HZNP: 10.90 )
HZNP' s 10-Year P/B Range
Min: 0.8   Max: 14.75
Current: 10.9

0.8
14.75
P/S 4.80
HZNP's P/S is ranked higher than
66% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. HZNP: 4.80 )
HZNP' s 10-Year P/S Range
Min: 1.47   Max: 19.46
Current: 4.8

1.47
19.46
EV-to-EBIT -61.24
HZNP's EV-to-EBIT is ranked lower than
53% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. HZNP: -61.24 )
HZNP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -61.24

Current Ratio 0.97
HZNP's Current Ratio is ranked lower than
51% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. HZNP: 0.97 )
HZNP' s 10-Year Current Ratio Range
Min: 0.16   Max: 4.39
Current: 0.97

0.16
4.39
Quick Ratio 0.92
HZNP's Quick Ratio is ranked higher than
55% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. HZNP: 0.92 )
HZNP' s 10-Year Quick Ratio Range
Min: 0.16   Max: 4.27
Current: 0.92

0.16
4.27

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.00
HZNP's Price/Median PS Value is ranked higher than
83% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. HZNP: 1.00 )
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.37   Max: 3.73
Current: 1

0.37
3.73

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPR.Germany
Horizon Pharma Inc is a specialty pharmaceutical company. It has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
» More Articles for NAS:HZNP

Headlines

Articles On GuruFocus.com
Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc. Oct 17 2014 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of A Oct 15 2014 
Horizon Pharma plc Reviews Future ACTIMMUNE(R) Opportunities at Analyst Day Oct 15 2014 
Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE(R) (Interferon gamma-1b) in Friedr Oct 15 2014 
Horizon Pharma plc Announces Presentation of ACTIMMUNE(R) Phase 2 Data in Friedreich's Ataxia Oct 15 2014 

More From Other Websites
ZetrOZ, Inc. Announces $5 Million Venture Loan Facility from Horizon Technology Finance to Fuel... Oct 20 2014
NRIFF: Nuvo Research Sells U.S. Pennsaid Rights To Horizon Oct 20 2014
HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Oct 17 2014
Nuvo Sells Pennsaid 2% U.S. Rights for US$45M to Horizon Pharma Oct 17 2014
Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc. Oct 17 2014
Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc. Oct 17 2014
HORIZON PHARMA PLC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements... Oct 14 2014
Horizon Pharma plc Reviews Future ACTIMMUNE(R) Opportunities at Analyst Day Oct 13 2014
Horizon Pharma plc Announces Presentation of ACTIMMUNE(R) Phase 2 Data in Friedreich's Ataxia Oct 09 2014
Horizon Pharma's Actimmune Gets Orphan Drug Designation Oct 07 2014
Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE(R) (Interferon gamma-1b) in... Oct 03 2014
Jazz Pharmaceuticals Uses New Cash To Buy For Growth Oct 03 2014
The Zacks Analyst Blog Highlights: Super Micro Computer, Horizon Pharma, Phibro Animal Health,... Oct 02 2014
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of... Oct 01 2014
The Bigger The Base The Higher Into Space It Goes Sep 29 2014
HORIZON PHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers Sep 26 2014
Horizon Pharma plc Announces Management Executive Committee and Commercial Restructuring Following... Sep 26 2014
HORIZON PHARMA PLC Financials Sep 24 2014
HORIZON PHARMA PLC Files SEC form 8-K, Other Events Sep 24 2014
Here are buying opportunities in small caps: Pro Sep 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK